• Corpus ID: 59353362

Smart Medication: Electronic Diary, Medication Management and Analysis Tool of Haemophilia Home Treatment: Development, Implementation, Test and Operating of a Telemedicine Platform

  title={Smart Medication: Electronic Diary, Medication Management and Analysis Tool of Haemophilia Home Treatment: Development, Implementation, Test and Operating of a Telemedicine Platform},
  author={Philipps-Universit{\"a}t Marbrug},
Ubiquitous computing based on high speed internet and mobile devices facilitate dramatically new possibilities in the health care sector. Patients with rare chronic diseases, often living far away from the medical center, benefit from telemedicine and telemonitoring in particular. We describe how a telemonitoring platform called “smart medication” developed by medical and IT experts can improve the care of patients with the rare chronic disease haemophilia. The study reports the experience of… 
2 Citations

Figures and Tables from this paper

Mobile health (mhealth): facilitators and barriers of the intention of use in patients with chronic illnesses
The findings of this research challenge the notion that privacy concerns are an obstacle for using mHealth and provide implications for designers of mHealth, health care professionals and policy-makers in order to enhance the use of m health.
The growing number of hemophilia registries: Quantity vs. quality
There is an urgent need for a pan‐European or global strategy that supports consistent data collection and harmonization of the database structures, and the convergence of scientific approaches.


Improved Surveillance of Haemophilia Home Treatment Using Mobile Phones
An overview of the new concept named “smart” provides an overview of how the use of telemetric systems may provide possibilities for online documentation and therefore early recognition of critical bleeding episodes or concentrate use.
Haemoassist™– a hand‐held electronic patient diary for haemophilia home care
The study shows that an electronic documentation system is feasible for haemophilia patients and provides the physician with the opportunity to more closely monitor patients.
E-health System for Monitoring of Chronic Diseases
A medical device for monitoring some vital parameters on patients with chronically diseases that alongside a software application, it provides an integrated solution of monitoring the evolution of the disease in order to optimize the treatment.
Telemedicine and remote patient monitoring.
Given the range of applications and technologies, evaluating the effectiveness of telemedicine means individually evaluating different combinations of technologies and clinical or other uses.
Home management of haemophilia
Home care was an essential prerequisite to the introduction of effective prophylactic factor replacement therapy, and the future holds the promise of factor concentrates for home use that have longer half‐lives, or can be administered by alternate routes.
Comparing hand‐held computers and paper diaries for haemophilia home therapy: a randomized trial
Although hand‐held computers did not result in increased accuracy, errors could be detected and corrected more rapidly and electronic data can more easily be verified, analysed and summarized than that from paper diaries.
The impact of information technology on haemophilia care
Summary.  The past decade has seen an explosion in the use of computers, data programs, hand‐held electronic devices and the Internet. How these advances impact on haemophilia management both now and
Perspectives from the Veterans Health Administration about opportunities and barriers in telemedicine
We used qualitative interviews to examine the perceptions of direct providers of telemedicine services, primary care providers (PCPs) and hospital administrators about opportunities and barriers to
Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators.
Although HIV infection and the presence of severe liver disease remain strong predictors of mortality, survival is significantly greater among hemophilics who receive medical care in HTCs, and those persons who had received care in an HTC had a significantly decreased risk of death.
Efficacy, safety and tolerability of recombinant factor VIII (REFACTO®) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria
This study confirms the efficacy, safety and tolerability of REFACTO in the treatment of patients with haemophilia A and emphasizes the benefit of postmarketing surveillance.